Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on May 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). NMS terminated the 2017 license agreement, alleging patent-inventorship and onvansertib development breaches.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- NMS terminated the 2017 license agreement, alleging patent-inventorship and onvansertib development breaches
- Dispute directly threatens Cardiff’s rights to develop and commercialize onvansertib under the NMS license
- Cardiff rejects termination as legally ineffective and intends to continue performing under the agreement
- Cardiff’s May 19 lawsuit seeks continued NMS performance, declaratory relief, and other remedies
- Litigation creates material uncertainty around patent ownership, licensing rights, and onvansertib’s development path
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.